...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Medical aspects of the National Centre For Oncological Hadrontherapy (CNAO-Centro Nazionale Adroterapia Oncologica) in Italy.
【24h】

Medical aspects of the National Centre For Oncological Hadrontherapy (CNAO-Centro Nazionale Adroterapia Oncologica) in Italy.

机译：意大利国家癌症强子疗法中心（CNAO-Centro Nazionale Adroterapia Oncologica）的医学方面。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

More than 20 hadrontherapy centres are active in the world and about 40,000 patients have been treated, almost 4000 with ions. Physical selectivity and high relative biologic efficiency (RBE) represent the rationale for using ions in the treatment of tumours. The clinical results are very promising and justify the construction of new centres. We present the main characteristics of CNAO (Centro Nazionale Adroterapia Oncologica) and its possible integration in a nationwide network. The Italian project started in 1991 thanks to the activity of the TERA Foundation and was financed by the Italian Government in 2002. The CNAO will be built in Pavia to start clinical activity in 2007. The equipment will include a synchrotron and 3 treatment rooms mainly devoted to carbon ions but able to deliver also protons. The Centre should be able to deliver up to 20,000 fractions / year. The realization of CNAO is part of a more ambitious project to set up an integrated national network. The need of hadrontherapy centresis defined by epidemiological studies based on Italian tumour registries showing that almost 900 patients can be electively treated with protontherapy and about 10,000 could be included in clinical trials. Considering that ions could be used for radioresistant tumours that affect about 25,000 new patients/year, we estimate that 10-15%, i.e. 3000-4000 patients would benefit from ion therapy. The realization of a nationwide network possibly linked to a larger European network will be very helpful in making available hadrontherapy for a large part of the population.
机译：世界上有超过20个强子治疗中心在运转，大约40,000名患者得到了治疗，其中将近4000名接受了离子治疗。物理选择性和较高的相对生物学效率（RBE）代表了使用离子治疗肿瘤的基本原理。临床结果非常有希望，并证明了新中心的建设是合理的。我们介绍了CNAO（Centro Nazionale Adroterapia Oncologica）的主要特征及其在全国网络中的可能集成。意大利项目于1991年开始，得益于TERA基金会的活动，该项目由意大利政府于2002年资助。该CNAO将在帕维亚建造，将于2007年开始临床活动。该设备将包括同步加速器和3个主要用于治疗的治疗室碳离子，但也可以传递质子。该中心每年应能够提供多达20,000个分数。 CNAO的实现是建立一个完整的国家网络的一项更宏大计划的一部分。由基于意大利肿瘤登记的流行病学研究确定的强子疗法中心治疗的需求表明，将近900名患者可以接受质子治疗，而大约10,000名患者可以纳入临床试验。考虑到离子可用于每年影响约25,000名新患者的放射线抗性肿瘤，我们估计10-15％的患者（即3000-4000名患者）将从离子治疗中受益。实现可能与更大的欧洲网络相联系的全国性网络，对于为大部分人口提供强子疗法非常有帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号